Skip to main content
. Author manuscript; available in PMC: 2024 Jan 5.
Published in final edited form as: Clin Cancer Res. 2023 Jul 5;29(13):2385–2393. doi: 10.1158/1078-0432.CCR-22-3321

Table 5.

Summary of lisaftoclax PK parameters following a single oral administration.

Analyte Dose
(mg)
Subject
Number
T1/2
(h)
Tmax
(h)
Cmax
(μg/mL)
AUC0-24
(h*μg/mL)
Lisaftoclax (APG-2575) 50 1 2.84 3 0.0391 0.261
100 1 3.85 6 0.229 1.80
200 2 3.84 ± 0.16 4 (4~4) 0.294 ± 0.004 2.41 ± 0.37
400 8 4.43 ± 0.57 6 (4~8) 0.822 ± 0.334 6.85 ± 2.91
600 7 4.68 ± 1.03 6 (4~8) 0.761 ± 0.298 7.81 ± 2.84
800 7 4.34 ± 0.53 4 (4~6) 0.982 ± 0.384 7.25 ± 2.24
1,000 6 6.10 ± 1.52 8 (6~8) 1.69 ± 1.22 18.3 ± 13.1
1,200 6 4.86 ± 1.01 6 (3~8) 1.20 ± 0.48 12.3 ± 4.82

Data was represented as Mean ± SD; Tmax was represented as Median (range).